Literature DB >> 15200122

Involvement of epidermal growth factor receptor-protein tyrosine kinase transactivation in endothelin-1-induced vascular contraction.

Yoshifumi Kawanabe1, Tomoh Masaki, Nobuo Hashimoto.   

Abstract

OBJECT: Endothelin-1 (ET-1) is one of the major inducers of vasospasm following subarachnoid hemorrhage (SAH). It is generally accepted that extracellular signal-regulated kinase 1 and 2 (ERK1/2) are involved in ET-1-induced vascular contraction. In addition, ET-1 transactivates epidermal growth factor receptor (EGFR) protein tyrosine kinase (PTK), which leads to ERK1/2 stimulation. Therefore, the authors examined whether EGFR-PTK transactivation contributes to ET-1-induced vascular contraction in this study.
METHODS: Mitogen-activated protein kinase inhibitor, PD98059, inhibited ET-1-induced ERK1/2 stimulation in rabbit basilar artery (BA) vascular smooth-muscle cells (VSMCs). Moreover, PD98059 inhibited ET-1-induced contraction of rabbit BA rings. A specific inhibitor of EGFR PTK, AG1478, inhibited ET-1-induced EGFR-PTK transactivation, ERK1/2 stimulation, and contraction of BA rings in a concentration-dependent manner. The concentration of AG1478 required for 50% inhibition of the ET-1-induced contraction of BA rings was similar to that for ET-1-induced EGFR-PTK transactivation. Furthermore, AG1478 also inhibited ET-1-induced BA vasospasm in vivo.
CONCLUSION: The results indicate that EGFR-PTK transactivation pathway plays an important role in ET-1-induced vascular contraction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15200122     DOI: 10.3171/jns.2004.100.6.1066

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase.

Authors:  Zheng Xu; Lu Cai
Journal:  J Mol Cell Cardiol       Date:  2015-04-10       Impact factor: 5.000

2.  Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed.

Authors:  Ibrahim F Benter; Mariam H M Yousif; Sioned M Griffiths; Mustapha Benboubetra; Saghir Akhtar
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 3.  Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.

Authors:  J Marc Simard; David Schreibman; E Francois Aldrich; Bernadette Stallmeyer; Brian Le; Robert F James; Narlin Beaty
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

Review 4.  The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments.

Authors:  Peter Solár; Alemeh Zamani; Klaudia Lakatosová; Marek Joukal
Journal:  Fluids Barriers CNS       Date:  2022-04-11

5.  DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum.

Authors:  Fernando S Carneiro; Fernanda R C Giachini; Victor V Lima; Zidonia N Carneiro; Kênia P Nunes; Adviye Ergul; Romulo Leite; Rita C Tostes; R Clinton Webb
Journal:  Can J Physiol Pharmacol       Date:  2008-06       Impact factor: 2.273

Review 6.  The epidermal growth factor receptor and its ligands in cardiovascular disease.

Authors:  Nader Makki; Kristina W Thiel; Francis J Miller
Journal:  Int J Mol Sci       Date:  2013-10-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.